OCT 08, 2020 6:00 AM PDT

Looking for Evidence-Based Oncology? T̶r̶y̶ Do Targeted Proteomics!

Sponsored by: LUMINEX
C.E. Credits: Florida CE P.A.C.E. CE
Speaker

Abstract

Every patient is different and so is every tumor! The term “personalized oncology” today is largely associated with sequencing approaches. Current publications proof more and more that only few people really benefit from sequencing their tumor genome leaving many patients underrepresented and underserved. With Reverse Clincial Engineering, we have designed an organoid-based, multi-omics driven pipeline that supports us in understanding each tumor the best possible way in a clinical setting. Timing is crucial when it comes to treating cancer patients. It has been well established, that chances of cure dramatically decrease from treatment line to treatment line. Using organoids for drug screening has been shown to be feasible by many groups for various tumor entities. We use multiple regions of the donor tumor to generate distinct patient-derived 3D (PD3D®) organoids in less than 4 weeks, screening all drugs that are considered by the oncologist, plus drugs that may have an approval for different tumor entities. In parallel, we perform DigiWest, a bead-based multiplexed western blot based on Luminex’ xMAP technology platform. Here we can interrogate a set of up to 200 (phospho) protein specific antibodies in parallel. In contrast to RNAseq, this delivers not only information about the expression, but also of the activation of signaling pathways, with the benefit of a significantly less complicated infrastructure in comparison to sequencing. From all sources, we compile a patient-specific dataset including histo-pathological data, FISH analysis, sequencing data, drug screening data and proteomic data we compile a comprehensive report for each patient which is reported to the tumor board to be discussed within a multidisciplinary team. In conclusion: We rethink oncology and use complementory technologies to put the patient in the focus, enabling patient and oncologist to make informed decisions at the right time.

Learning Objectives:

1. Show that a “sequencing alone” approach is not in the patient’s best interest

2. Convince the audience that using a multi layered omics approach helps understanding the biology and as such opening new treatment options


Show Resources
You May Also Like
MAY 11, 2021 10:00 AM PDT
C.E. CREDITS
MAY 11, 2021 10:00 AM PDT
Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
JUN 09, 2021 7:00 AM PDT
C.E. CREDITS
JUN 09, 2021 7:00 AM PDT
Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
JUL 15, 2021 8:00 AM PDT
C.E. CREDITS
JUL 15, 2021 8:00 AM PDT
Date: July 15, 2021 Time: 8:00am (PDT), 11:00am (EDT) High dimensional full spectrum flow cytometry grants unprecedented access to previously unattainable parameters in cellular biology. Flu...
OCT 12, 2021 9:00 AM PDT
C.E. CREDITS
OCT 12, 2021 9:00 AM PDT
Date: October 12, 2021 Time: 9:00am (PDT), 12:00pm (EDT) SCIEX’s next-generation Biologics Explorer software is an innovative platform for the comprehensive and deep characterization o...
JUL 15, 2021 9:00 AM PDT
JUL 15, 2021 9:00 AM PDT
Date: July 15, 2021 Time: 9:00am (PDT), 12:00pm (EDT) The Pisces workflow robust, easy-to-use, end-to-end multi-omics solution for highly multiplexed targeted Spatial RNA analysis. VeranomeB...
Loading Comments...
Show Resources